Science AI Journal
Medicine · Research topic

Open research questions in Atrial Fibrillation Management and Outcomes

120 unresolved questions extracted from the limitations and future-work sections of 710 Atrial Fibrillation Management and Outcomes papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • Although some studies suggest that sarcopenia may be associated with an increased risk of atrial fibrillation (AF), the evidence supporting this association remains insufficient.

    Association between sarcopenia and atrial fibrillation: a meta-analysis · 2026 · DOI

  • BackgroundLeft atrial volume index (LAVI) reflects chronic left atrial remodelling in heart failure with preserved ejection fraction (HFpEF), but its nonlinear, haemodynamic, and time-varying associations with newly documented atrial fibrillation (AF) remain uncertain.

    Left Atrial Remodeling, Hemodynamic Burden, and Time-Varying Risk of Newly Documented Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction · 2026 · DOI

  • ABSTRACT Background Little is known about the efficacy and safety of pulsed field ablation (PFA) for repeat ablation procedures for patients with recurrent atrial fibrillation (AF) after pulmonary vein (PV) isolation.

    Efficacy and Safety of Pulsed Field Ablation During Repeat Procedures for Treatment of Recurrent Atrial Arrhythmias After Pulmonary Vein Isolation · 2026 · DOI

  • However, the association between CTI and late atrial fibrillation (AF) recurrence after radiofrequency catheter ablation (RFCA) has not been well established.

    Predictive value of the C-reactive protein–triglyceride–glucose index for late atrial fibrillation recurrence after radiofrequency catheter ablation: a retrospective cohort study · 2026 · DOI

  • BackgroundThree pulsed-field ablation (PFA) systems are FDA-approved for atrial fibrillation (AF), yet whether their safety profiles differ from each other and from radiofrequency (RF) ablation has not been systematically characterized using real-world adverse event data.

    Platform-Specific Safety of Pulsed Field Ablation for Atrial Fibrillation: A MAUDE Analysis · 2026 · DOI

  • Atrial fibrillation (AF) is associated with an increased risk of neurological morbidity, yet its impact on cerebral perfusion and neuro-cardiorespiratory regulation remains incompletely understood.

    Cerebral hypoperfusion and altered neuro-cardiorespiratory coupling in atrial fibrillation · 2026 · DOI

  • Whilst there is clinical direction for anticoagulation in patients with AF, there are no standardised indications for intermediate durations of AHREs and oral anticoagulation is largely determined on an individual basis.

    Device-Detected Atrial High-Rate Episodes and Risk of Ischaemic Stroke and Progression to Atrial Fibrillation: A Systematic Review and Meta-Analysis · 2026 · DOI

  • Whether the TyG index is associated with ischemic stroke burden and recurrent cerebrovascular events in patients with different AF phenotypes remains insufficiently characterized.

    Triglyceride–Glucose Index and Ischemic Stroke Burden in Permanent Versus Paroxysmal Atrial Fibrillation: A Real-World Retrospective Cohort Study · 2026 · DOI

  • Targeted monitoring and secondary prevention strategies are warranted, especially for AFDAS patients with prior cerebrovascular or cardiac comorbidities.

    Clinical characteristics and risk factors of atrial fibrillation detection after acute ischemic stroke · 2026 · DOI

  • ABSTRACT Background Amiodarone is frequently co‐prescribed with direct oral anticoagulants (DOACs) in atrial fibrillation (AF), but its impact on early bleeding risk after DOAC initiation in older adults remains uncertain.

    Early Bleeding Risk After DOAC Initiation With Concomitant Amiodarone in Older Adults With Atrial Fibrillation · 2026 · DOI

  • Roughly 84% of the survival benefit remained unmediated; this residual effect is consistent with partial mitigation of the endogenous catecholaminergic surge, although its exact contribution remains undetermined.

    Association of anti-catecholaminergic antiarrhythmic drugs with survival in sepsis-associated new-onset atrial fibrillation · 2026 · DOI

  • Therefore, interpretation of the present findings should remain cautious, and future investigations should focus on defining clear patient selection strategies and procedural standardization to ensure consistent outcomes. It is also important to acknowledge that the current evidence base is limited by the 180 lack of standardized criteria for patient selection and variations in procedural techniques among studies.

    Ethanol Infusion into the Vein of Marshall Enhances Mitral Isthmus Block and Reduces Atrial Fibrillation Recurrence: A Comprehensive Meta-Analysis · 2026 · DOI

  • Although the TAILORED AF trial demonstrated the efficacy of spatio‐temporal dispersion electrogram (STDE) ablation as additional treatment for PVI, comparisons between STDE and low‐voltage zone (LVZ) remain unclear.

    Comparison of Spatio‐Temporal Dispersion Electrogram Ablation and Low Voltage Zone Ablation in Patients With Persistent Atrial Fibrillation · 2026 · DOI

  • 1733008 studies with larger sample sizes, longer follow-up periods, formal internal validation, and external validation cohorts are warranted to confirm and extend these findings.

    Construction of a regression model and post-procedure care strategy for predicting atrial fibrillation recurrence risk after radiofrequency ablation using combined P-wave electrocardiographic markers and serum · 2026 · DOI

  • This study focuses on NVAF patients with CHA₂DS₂-VA scores ≤1, a clinically important subgroup in which stroke prevention strategies remain controversial.

    Development and validation of interpretable machine learning models for predicting stroke in NVAF patients with CHA2DS2-VA scores ≤1 · 2026 · DOI

  • ABSTRACT Background In left atrial appendage closure (LAAC) using newer‐generation WATCHMAN FLX/FLX Pro devices, managing borderline‐sized LAA within overlapping zones is common, but optimal device sizing strategies remain unknown.

    Outcomes of Different Device Sizing Strategies Using the Newer‐Generation WATCHMAN Devices for Closure of Borderline‐Sized Left Atrial Appendage · 2026 · DOI

  • Background and Purpose Patients with ischemic stroke with both atrial fibrillation (AF) and large artery atherosclerosis (LAA) represent therapeutic challenges, and the optimal antithrombotic regimen remains uncertain.

    Combined Oral Anticoagulant and Antiplatelet for Atrial Fibrillation and Cerebral Atherosclerosis: A Meta-Analysis · 2026 · DOI

  • Background The relationship between blood pressure (BP) levels upon hospital admission and in-hospital stroke in patients hospitalized with atrial fibrillation (AF) remains unclear and has been complicated by current guidelines with two different thresholds (≥140/90 mm Hg and ≥130/80 mm Hg) for treating hypertension.

    Association between blood pressure levels and risk of stroke in patients with atrial fibrillation: results from a prospective registry in Xinjiang, China · 2026 · DOI

  • Several limitations of this study should be ac- knowledged. Fi- nally, the analysis was restricted to in-hospital out- comes, and the long-term clinical consequences of POAF, including late recurrence of atrial fibrillation or thromboembolic events, could not be evaluated.

    A high-risk perioperative atrial fibrillation phenotype and early outcomes after isolated coronary artery bypass grafting · 2026 · DOI

  • This study has several limitations that warrant consideration. First, the analyses were based on nationally aggregated data, which may obscure substantial regional and subnational heterogeneity in the burden of AF/AFL. As a result, the findings may have limited applicability for informing individual-level research or locally tailored interventions. Second, reliance on secondary data sources may introduce potential biases, including inaccuracies in data collection, misclassification or misdiagnosis of disease, and reporting bias, particularly in low-SDI settings where limited healthcare access and weaker surveillance systems may lead to underdiagnosis and incomplete cause-of-death registration. Third, estimates from the GBD framework are model-based and depend on statistical assumptions and data imputation, especially in regions with sparse or low-quality data, which may introduce uncertainty and affect the robustness of the results. Although uncertainty intervals are provided, they may not fully capture all sources of systematic error. Fourth, temporal trends may be influenced by changes in diagnostic criteria, coding practices, and the accessibility of healthcare services over time, which can compromise the comparability of estimates across years and, consequently, reduce the accuracy of ARIMA models in forecasting future trends. Xu et al. Vessel Plus. 2026;10:32 Page 13 of 15 In addition, the GBD database categorizes multiple conditions into relatively broad disease groups, which may mask specific clinical subtypes or contextual health issues that warrant targeted prevention and management strategies. Future studies incorporating more granular, regionally representative, and individual-level data are needed to better characterize local patterns of AF/AFL burden and to support the development of more precise and effective public health interventions.

    Epidemiological trends in the burden of atrial fibrillation and atrial flutter in China (1990-2023) · 2026 · DOI

  • DOAC reversal is a rapidly evolving field, with new agents and strategies under development to address limitations of current therapies. Future directions focus on developing universal, safer, and more accessible reversal agents, optimizing clinical protocols, and expanding options for new classes of anticoagulants. Two investigational reversal agents for factor Xa inhibitors are currently under development. Ciraparantag is a small molecule that reverses the effects of direct and indirect FXa inhibitors through charge-based binding. It acts rapidly after intravenous administration and produces sustained reversal of effects for up to 24 hours. Early-phase studies in healthy volunteers have demonstrated dose-dependent reversal of apixaban, rivaroxaban, and edoxaban, with good tolerability. A phase II trial is ongoing. VMX-C001 is a modified recombinant factor X that restores thrombin generation without excessive rebound. Preclinical studies show a favorable safety profile, and a phase I trial is underway to evaluate its efficacy in reversing FXa inhibitors in humans (23). Take-away Lesson This case underscores the need for greater awareness among clinicians regarding the potential value of DOAC- level measurement in frail older patients presenting with bleeding or renal impairment. Although DOACs are generally considered safe and predictable, measurement can provide critical information to guide decisions about discontinuation, reversal, and individualized management. Older and frail patients, often underrepresented in pivotal trials, are particularly vulnerable to drug accumulation and bleeding due to age-related pharmacokinetic variability, comorbidities, and polypharmacy. Furthermore, the case highlights the importance of familiarity with available reversal strategies and their appropriate indications. Broader awareness of both diagnostic and therapeutic options may support earlier recognition of DOAC- related complications and safer, more tailored care in this population. Table 1. Overview of currently available DOAC reversal strategies.

    Silent Danger: Dabigatran Build-up in a Frail Nonagenarian-rethinking DOAC Monitoring in Acute Care · 2026 · DOI

  • Our findings should be interpreted considering the study’s limitations. The study databases lacked several variables that could affect switching, including psychosocial factors, laboratory data, patient preferences, prescriber characteris- tics, provider preferences, and actual reasons for switching. We also lacked data on contextual factors such as income changes, insurance coverage, adverse effects, drug interac- tions, and hospital formulary changes. These limitations impede our ability to assess how broader systemic factors affect OAC switching patterns over time. Switches involving edoxaban were not described because of insufficient exposed patients. A potential limitation of the cox model is the risk of immortal time bias, as covariates such as hospitalizations occurring within 90 days before switching were measured post-baseline without accounting for the time-dependent nature. The Cox models treated death and discontinuation as censoring under the assumption of non-informative cen- soring. Lastly, a maximum follow-up of 2 years for the cox model may limit the observation of late switches or rare exposures. These limitations should be considered when interpreting the strength of associations reported.

    Oral anticoagulant switching in patients with atrial fibrillation: a long-term cohort study using population-level administrative data · 2026 · DOI

  • Future research should focus on well-designed pro- spective multicenter studies to better understand determinants of anticoagulation control, as well as inter- ventional studies evaluating the effectiveness of strategies such as pharmacist-led anticoagulation clinics, point-of- care INR testing, and standardized dosing protocols.

    Pooled estimate of anticoagulation control with warfarin therapy among adult patients in Ethiopia: a systematic review and meta-analysis · 2026 · DOI

  • While this systematic review and meta-analysis provide the first pooled estimate of anticoagulation control in Ethiopia, several limitations must be acknowledged. First, the relatively small number of included studies (n = 6) may limit the statistical power of the meta-analysis and the robustness of the pooled estimate. With a limited study pool, the stability of the final result is more suscep- tible to the influence of individual study characteristics. Second, there was significant statistical heterogene- ity observed across the included studies. This variabil- ity likely stems from differences in study populations, geographical settings (urban vs. rural), and the level of healthcare facilities (teaching vs. general hospitals). Such heterogeneity implies that the pooled TTR should be interpreted with caution, as clinical practices and patient adherence may vary across the diverse Ethiopian health- care landscape. Third, the methods used to define and calculate TTR were not uniform across all primary studies. Differences in calculation approaches such as the Rosendaal method versus the percentage of tests in range can impact the comparability of data and may introduce measurement bias into the pooled results. Fourth, although we assessed publication bias using funnel plots and Egger’s test, these methods have reduced sensitivity when fewer than ten studies are included. Consequently, we cannot entirely rule out the possibility that smaller, unpublished studies with differ- ent outcomes may exist. Finally, our search was restricted to articles published in the English language, which may have excluded relevant local evidence published in other languages, potentially introducing a degree of language bias into our synthesis.

    Pooled estimate of anticoagulation control with warfarin therapy among adult patients in Ethiopia: a systematic review and meta-analysis · 2026 · DOI

  • COMPETENCY IN MEDICAL KNOWLEDGE: Clinical trials indicated improved mortality in patients with AF when SR is maintained. Although stroke and HF are clinically appreciated complications of AF, the impact of AF on ventricular arrhythmias and potentially SCD is less understood. Our study establishes that AF promotes ventricular arrhythmogenesis. Electrophysiological investigations of human and murine ventricular myocardium have revealed for the first time an increased cellular arrhythmic trigger in AF based on the arrhythmic excitation of ventricular cardiomyocytes. These mechanisms are well established drivers of ventricular arrhythmia. TRANSLATIONAL OUTLOOK: Future studies are needed to characterize the proarrhythmic ventricular phenotype upon AF in vivo and to evaluate the effects of SR restoration on ventricular tachycardia and ventricular fibrillation. Our study highlights an underappreciated, but potentially prognosis-relevant complication of AF. Further work is needed to define potential implications on clinical management of AF patients. R E F E R E N C E S 1. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. https://doi.org/10.1161/ 2014;129(8):837–847. CIRCULATIONAHA.113.005119 2. Eisen A, Ruff CT, Braunwald E, et al. Sudden cardiac death in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc. 2016;5(7). https://doi.org/10.1161/ JAHA.116.003735 3. Chen LY, Sotoodehnia N, B � u � zková P, et al. Atrial fibrillation and the risk of sudden cardiac death: the atherosclerosis risk in communities study and cardiovascular health study. JAMA Intern Med. 2013;173(1):29–35. https://doi.org/ 10.1001/2013.jamainternmed.744 4. Bardai A, Blom MT, van Hoeijen DA, van Deutekom HWM, Brouwer HJ, Tan HL. Atrial fibrillation is an independent risk factor for ventricular fibrillation: a large-scale populationbased case-control study. Circ Arrhythm Electrophysiol. 2014;7(6):1033–1039. https://doi.org/10. 1161/CIRCEP.114.002094 5. Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378(5):417–427. https://doi.org/10.1056/NEJMoa1707855 6. Prabhu S, Taylor AJ, Costello BT, et al. Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA- MRI study. J Am Coll Cardiol. 2017;70(16):1949– 1961. https://doi.org/10.1016/j.jacc.2017.08.041 7. Sohns C, Fox H, Marrouche NF, et al. Catheter ablation in end-stage heart failure with atrial fibrillation. N Engl J Med. 2023;389(15):1380– 1389. https://doi.org/10.1056/NEJMoa2306037 fibrillation. N Engl J Med. 2020;383(14):1305– 1316. https://doi.org/10.1056/NEJMoa2019422 9. Pabel S, Knierim M, Stehle T, et al. Effects of atrial fibrillation on the human ventricle. Circ Res. 2022;130(7):994–1010. https://doi.org/10.1161/ CIRCRESAHA.121.319718 10. Dosdall DJ, Ranjan R, Higuchi K, et al. Chronic atrial fibrillation causes left ventricular dysfunction in dogs but not goats: experience with dogs, goats, and pigs. Am J Physiol Heart Circ Physiol. 2013;305(5):H725–H731. https://doi.org/10.1152/ ajpheart.00440.2013 11. Hartmann N, Pabel S, Herting J, et al. Antiarrhythmic effects of dantrolene in human diseased cardiomyocytes. Heart Rhythm. 2017;14(3):412– 419. https://doi.org/10.1016/j.hrthm.2016.09. 014 8. Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial 12. Bommer T, Knierim M, Unsöld J, et al.

    Atrial Fibrillation Increases Proarrhythmic Mechanisms in the Ventricle · 2026 · DOI

Most-cited papers in Atrial Fibrillation Management and Outcomes

Most recent work

Find a gap in your own Atrial Fibrillation Management and Outcomes sub-topic

This page shows what the Atrial Fibrillation Management and Outcomes literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Substance Abuse Treatment and Outcomes
989 open questions
Artificial Intelligence in Healthcare and Education
607 open questions
Attention Deficit Hyperactivity Disorder
448 open questions
Physical Activity and Health
436 open questions
Smoking Behavior and Cessation
402 open questions
Innovations in Medical Education
364 open questions
Dementia and Cognitive Impairment Research
363 open questions
HIV/AIDS Research and Interventions
342 open questions
120 open questions have been extracted from the limitations and future-work passages of 710 Atrial Fibrillation Management and Outcomes papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.